Abstract
Anterior segment neovascularization, like posterior segment neovascularization, is a consequence of retinal ischemia mediated by increased intraocular levels of vascular endothelial growth factor (VEGF). It differs in that it generally requires higher levels of VEGF to induce anterior segment neovascularization than to induce posterior segment neovascularization. Because levels of VEGF correlate with area of retinal ischemia, it is rare for anterior segment neovascularization (ASNV) to arise after branch retinal vein occlusion (BRVO). It can be seen occasionally after hemispheric BRVO, but is never seen after macular BRVO. Therefore, this chapter mostly concerns central retinal vein occlusion (CRVO). Abbreviations commonly used in discussing ASNV are listed in Table 11.1. Each abbreviation will be spelled out at its first occurrence.
Keywords
- Vascular Endothelial Growth Factor
- Retinal Vein Occlusion
- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
- Retinal Ischemia
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D’Amore PA, Miller JW. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66–71.
Aiello LP, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.
Ambati J, Chalam KV, Chawla DK, D’Angio CT, Guillet EG, Rose SJ, Vanderlinde RE, Ambati BK. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161–6.
Anderson DM, Morin JD, Hunter WS. Rubeosis iridis. Can J Ophthalmol. 1971;6:183–8.
Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina. 2006;26:352–6.
Bandello F, Brancato R, Lattanzio R, Falcomata B, Malegori A. Biomicroscopy versus fluorescein angiography of the iris in the detection of diabetic iridopathy. Graefes Arch Clin Exp Ophthalmol. 1993;231:444–8.
Bandello F, Brancato R, Lattanzio R, Galdini M, Falcomata B. Relation between iridopathy and retinopathy in diabetes. Br J Ophthalmol. 1994;78:542–5.
Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008;28:59–61.
Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120:1644–50.
Browning DJ, Rotberg MH. The relationship of diabetic retinopathy and glaucoma. In: Browning DJ, editor. Diabetic retinopathy: evidence based management. New York: Springer; 2010. p. 325–47.
Browning DJ, Scott AQ, Peterson CB, Warnock J, Zhang Z. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology. 1998;105:776–84.
Chan CK, Ip MS, VanVeldhuisen PC, Score Study Group, et al. Score study report #11: incidents of neovascular events in eyes with retinal vein occlusion. Ophthalmology. 2011;118:1364–72.
Coleman SL, Green WR, Patz A. Vascular tufts of the pupillary margin of the iris. Am J Ophthalmol. 1977;83:881–3.
Dahlmann AH, Benson MT. Spontaneous hyphema secondary to iris vascular tufts. Arch Ophthalmol. 2001;119:1728.
Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (avastin) injection. Retina. 2006;26:354–6.
Davies N. Letter. Eye. 2001;15:688–91.
Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc. 1996;94:471–504.
Evans K, Wishart PK, McGalliard JN. Neovascular complications after central retinal vein occlusion. Eye. 1993;7:520–4.
Fong ACO, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L, Zegarra H, Nadel AJ, Johnson RN. Central retinal vein occlusion in young adults (papillophlebitis). Retina. 1992;12:3–11.
Fuller JJ, Mason III JO, White Jr MF, McGwin Jr G, Emond TL, Feist RM. Retinochoroidal collateral veins protect against anterior segment neovascularization after central retinal vein occlusion. Arch Ophthalmol. 2003;121:332–6.
Funatsu H, Yamashita H, Mimura T, Noma H, Nakamura S, Hori S. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye. 2007;21:377–82.
Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol. 1978;22:291–312.
Gutman FA. Discussion. Ophthalmology. 1982;89:783–4.
Hamanaka T, Akabane N, Yajima T, Takahashi T, Tanabe A. Retinal ischemia and angle neovascularization in proliferative diabetic retinopathy. Am J Ophthalmol. 2001;132:648–58.
Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994;42:109–32.
Hayreh SS. Evidence-based recommendations for neovascular glaucoma. Ophthalmology. 2003;110:1–2.
Hayreh SS, Hayreh MS. Hemi-central retinal vein occlusion: pathogenesis, clinical features, and natural history. Br J Ophthalmol. 1994;78:798–9.
Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early phase. Graefes Arch Clin Exp Ophthalmol. 1990;228:201–17.
Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118:119–33.
Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion-III: incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90:488–506.
Hayreh SS, Rubenstein L, Podhajsky P. Argon laser photocoagulation in treatment of branch retinal vein occlusion. A prospective clinical trial. Ophthalmologica. 1993;206:1–14.
Hikichi T, Konno S, Trempe CL. Role of the vitreous in central retinal vein occlusion. Retina. 1995;15:29–33.
Hvarfner C, Larsson J. Is optic nerve head swelling of prognostic value in central retinal vein occlusion? Graefes Arch Clin Exp Ophthalmol. 2003;241:463–7.
Jensen VA, Lundbaek K. Fluorescence angiography of the iris in recent and long-term diabetics. Acta Ophthalmol. 1968;46:584–5.
John T, Sassani JW, Eagle RC. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;1983:721–8.
Keenan JM, Dodson PM, Kritzinger EE. Are there medical conditions specifically underlying the development of rubeosis in central retinal vein occlusion? Eye. 1993;7:407–10.
Kottow MH. Iris neovascular tufts. Arch Ophthalmol. 1980;98:2084.
Kubota T, Tawara A, Hata T, Khalil A, Inomata H. Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. Br J Ophthalmol. 1996;80:750–4.
Laatikainen L. Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma. Br J Ophthalmol. 1977;61:278–84.
Laatikainen L, Blach RK. Behavior of the iris vasculature in central retinal vein occlusion: a fluorescein angiographic study of the vascular response of the retina and the iris. Br J Ophthalmol. 1977;61:272–7.
Laatikainen L, Kohner EM, Khoury D, Blach RK. Panretinal photocoagulation in central retinal vein occlusion: a randomized controlled clinical study. Br J Ophthalmol. 1977;61:741–53.
Lattanzio R, Gimeno AT, Parodi MB, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica. 2011;225:135–43.
Lindblom B. Fluorescein angiography of the iris in the management of eyes with central retinal vein occlusion. Acta Ophthalmol Scand. 1998;76:188–91.
Little HL, Rosenthal AR, Dellaporta A, Jacobson DR. The effect of panretinal photocoagulation on rubeosis iridis and neovascular glaucoma. Am J Ophthalmol. 1976;81:804–9.
Magargal LE, Brown GC, Augsburger JJ, Donoso LA. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central retinal vein obstruction. Ophthalmology. 1982;89:780–4.
Magargal LE, Brown GC, Augsburger JJ, Parrish RK. Neovascular glaucoma following central retinal vein obstruction. Ophthalmology. 1981;88:1095–101.
Magargal LE, Donoso LA, Sanborn GE. Retinal ischemia and risk of neovascularization following central retinal vein obstruction. Ophthalmology. 1982;89:1241–5.
Malecaze F, Clamens S, Simorre-Pinnatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476–82.
Mason G. Iris neovascular tufts. Ann Ophthalmol. 1980;12:420–2.
May DR, Klein ML, Peyman G, Raichand M. Xenon arc panretinal photocoagulation for central retinal vein occlusion: a randomized prospective study. Br J Ophthalmol. 1979;63:725–34.
Nomura T, Furukawa H, Kurinoto S. Development and classification of neovascular glaucoma in diabetic eye disease: histopathological study. Acta Ophthalmol Soc Jpn. 1976;86:166–75.
Nork TM, Tso MOM, Duvall J, Hayreh SS. Cellular mechanisms of iris neovascularization secondary to retinal vein occlusion. Arch Ophthalmol. 1989;107:581–6.
Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularization. Graefes Arch Clin Exp Ophthalmol. 1994;232:199–204.
Ohrt V. Rubeosis iridis diabetica. Acta Ophthalmol. 1958;36:556–8.
Parodi MB, Friberg TR, Pedio M, Fiotti N, Di Stefano G, Ravalico G. Panretinal photocoagulation and photodynamic therapy for anterior segment neovascularization secondary to ischemic central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2007;38:94–9.
Quinlan P, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990;110:118–23.
Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol. 2004;122:317–21.
Roth SM, Brown GC. The diagnosis and management of rubeosis iridis. Clin Signs Ophthalmol. 1989;10:1–15.
Sanborn GE, Symes DJ, Magaragal LE. Fundus-iris fluorescein angiography: evaluation of its use in the diagnosis of rubeosis iridis. Ann Ophthalmol. 1986;18:52–8.
Sanborn GE, Magargal LE. Characteristics of the hemispheric retinal vein occlusion. Ophthalmology. 1984;91:1616–26.
Schulze RR. Rubeosis iridis. Am J Ophthalmol. 1967;63:487–95.
Servais GE, Thompson HS, Hayreh SS. Relative afferent pupillary defect in central retinal vein occlusion. Ophthalmology. 1986;93:301–3.
Sinclair SH, Gragoudas ES. Prognosis for rubeosis iridis following central retinal vein occlusion. Br J Ophthalmol. 1979;63:735–43.
Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1990;108:869–72.
Steel DHW, Habib MS, Park S, Hildreth AJ, Owen RI. Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy the predictive value of inner sclerostomy site ultrasonography. Ophthalmology. 2008;115:525–32.
Tauber J, Lahav M, Erzurum SA. New clinical classification for iris neovascularization. Ophthalmology. 1987;94:542–4.
Teich SA, Walsh JB. A grading system for iris neovascularization-prognostic implications for treatment. Ophthalmology. 1981;88:1102–6.
Terasaki H, Miyake Y, Awaya S. Fluorescein angiography of peripheral retina and pars plana during vitrectomy for proliferative diabetic retinopathy. Am J Ophthalmol. 1997;123:370–6.
The Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol. 1993;111:1087–95.
The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion, the central vein occlusion study group M report. Ophthalmology. 1995;102:1425–33.
The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486–91.
The Central Vein Occlusion Study Group N Report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology. 1995;102:1434–44.
Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002;133:373–85.
Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964–70.
Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–7.
Vadala G, Zanini A, Favero C, Brogliatti B, Boles Carenini B. Evaluation of the clinical course of central retinal vein occlusion in eyes with and without glaucoma. Acta Ophthalmol Scand. 1997;75(S224):16–7.
Vannas A. Fluorescein angiography of the vessels of the iris. Acta Ophthalmol. 1969;105:1–75.
Wand M, Dueker DK, Aiello LM, Grant WM. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol. 1978;86:332–9.
Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol. 1978;10:488–91.
Weiter JJ, Zuckerman R. The influence of the photoreceptor-RPE complex on the inner retina. Ophthalmology. 1980;87:1133–9.
Williamson T, Rumley A, Lowe GDO. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol. 1996;80:203–8.
Williamson TH, Baxter GM. Central retinal vein occlusion, an investigation by color Doppler imaging. Ophthalmology. 1994;101:1362–72.
Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1979;86:1931–9.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Browning, D.J. (2012). Anterior Segment Neovascularization in Retinal Vein Occlusion. In: Retinal Vein Occlusions. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3439-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3439-9_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3438-2
Online ISBN: 978-1-4614-3439-9
eBook Packages: MedicineMedicine (R0)